

# Integration of serial self-testing for COVID-19 as part of contact tracing in the Brazilian public health system: A pragmatic trial protocol

Short Title: Serial self-testing for COVID-19 in the Brazilian public health system

## Authors and Affiliations

Rebecca K. Green<sup>1</sup>, Camilo Manchola<sup>2</sup>, Emily Gerth-Guyette<sup>1</sup>, Michelle Oliveira Silva<sup>3</sup>, Raissa Stephanie<sup>3</sup>, Tainá dos Santos Soares<sup>4</sup>, Luiza Bastos Gottin<sup>2</sup>, Milena Coelho<sup>2</sup>, Kimberly E. Green<sup>1</sup>, Alexandre Dias Tavares Costa<sup>4</sup>, Dhélio Batista Pereira<sup>3</sup>

<sup>1</sup>*PATH; Seattle, WA, United States*

<sup>2</sup>*Global Health Strategies; Rio de Janeiro, RJ, Brazil*

<sup>3</sup>*Centro de Pesquisa em Medicina Tropical de Rondônia (CEPEM); Porto Velho, RO, Brazil*

<sup>4</sup>*Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Fiocruz Paraná; Curitiba, PR, Brazil*

## Data Availability and Registration

The analytic dataset from this study will be published when the results are reported. This trial is registered at ISCTRN (ISRCTN91602092).

## Abstract

- 1 **Background:** The coronavirus disease (COVID-19) pandemic has led to an unprecedented public health
- 2 crisis. Insufficient testing continues to limit the effectiveness of the global response to the COVID-19
- 3 pandemic. Molecular testing methods such as reverse transcriptase polymerase chain reaction (RT-PCR)
- 4 continue to be highly centralized and are a sub-optimal option for population surveillance. Rapid antigen
- 5 tests (Ag-RDTs) offer multiple benefits including low costs, high flexibility to conduct tests in a wide
- 6 variety of settings, and faster return of results. Recently, self-test Ag-RDTs (STs) have gained approval in
- 7 several markets and offer the possibility to expand testing, reaching at-risk populations. While STs have

8 the potential to assist the COVID-19 response, test result integrity, reporting, and appropriate linkage to  
9 care continue to hinder the widespread implementation of self-testing programs.

10 **Methods:** This protocol presents a mixed-methods pragmatic trial (ISRCTN91602092) to better  
11 understand the feasibility of self-testing as part of a contact tracing strategy within the Brazilian public  
12 health system. Approximately 604 close contacts of 150 index cases testing positive for COVID-19 will be  
13 enrolled. Close contacts will be randomized to either serial (daily) self-testing over a 10-day follow-up  
14 period or a more traditional approach to contact tracing with a professional Ag-RDT at one time point  
15 post-exposure. Usability workshops and focus group discussions will also be conducted.

16 **Discussion:** This study protocol presents a comprehensive plan to assess the effectiveness, operational  
17 feasibility, and stakeholder preferences of a serial self-testing strategy for contact tracing within the  
18 Brazilian public health system. Our results will contribute to better understanding of the feasibility of a  
19 self-testing strategy within the public sector. Potential risks and limitations are discussed. Our findings  
20 will have important implications as governments continue working to mitigate the impact of COVID-19,  
21 particularly in the context of where to direct limited resources for testing and healthcare infrastructure.

## 22 Introduction

23 The coronavirus disease (COVID-19) pandemic led to an unprecedented public health crisis. Insufficient  
24 testing continues to limit the effectiveness of both the local and global response to the pandemic.  
25 Isolation and quarantine guidelines continue to evolve yet primarily rely on case identification and  
26 subsequent behavior modification for infected or exposed individuals. In many settings, the gold  
27 standard for COVID-19 diagnosis is reverse transcription polymerase chain reaction (RT-PCR), which is  
28 plagued by sparse availability of supplies, higher cost, slow turnaround times, and its highly centralized  
29 nature (1). These challenges make RT-PCR difficult to deploy widely and therefore not an optimal

30 candidate test as a public health tool for population surveillance and effectively interrupting  
31 transmission chains (2).

32 Rapid antigen tests (Ag-RDTs) for professional and self-test use offer multiple benefits in comparison to  
33 RT-PCR, including low costs and increased portability. Ag-RDTs can expand access to COVID-19 testing in  
34 places that do not have molecular testing capacity and results can be returned quickly, facilitating faster  
35 reporting and subsequent linkage to care. WHO recommends use of rapid antigen tests and self-tests for  
36 kits meeting minimum performance requirements in priority use cases (3–6). Further, rapid antigen tests  
37 may be more suitable in settings where people have been previously infected and molecular testing  
38 methods continue to return positive results due to residual viral fragments.

39 Successful strategies to broaden access to testing include the use of self-tests (STs) (7–9). Self-testing  
40 regimens for COVID-19 are a promising method to identify infectious individuals, interrupt transmission  
41 chains, and reduce demand on health facilities while addressing many of the usual barriers to uptake of  
42 services (2,10,11). In addition to enabling more timely isolation to minimize onward transmission, swift  
43 diagnosis can also prompt clinical intervention when needed, which may improve individual patient  
44 prognosis, particularly given the availability of new antivirals. Self-testing has shown high levels of  
45 acceptability, with many countries implementing large-scale programs to access at-home tests for free,  
46 and can increase equity by providing more testing options (7,12). In short, there is evidence that self-  
47 testing for COVID-19 is feasible and acceptable, with both national and global recommendations to use  
48 self-tests and some specific products receiving emergency use authorization from the US Food and Drug  
49 Administration (FDA) and WHO (13,14).

50 While self-testing has the potential to contribute significantly to the COVID-19 response, as with any  
51 rapid diagnostic, it also comes with limitations. Firstly, available antigen tests may have variable  
52 performance in asymptomatic individuals (13,15). False negative results may prompt infected individuals

53 to stop self-isolation and thereby contribute to virus transmission, while false positive results may lead  
54 to unnecessary stress, anxiety, and absences from work, school, and social activities. Secondly, self-  
55 testing results may not be reported and therefore missed by local and national health authorities.  
56 However, WHO guidelines describe the overall benefits of self-testing as outweighing these limitations.  
57 Clear communication on actions for positive and negative results, relevant support tools, efficient links  
58 to post-test counselling and easy access to results reporting are needed as key components of self-  
59 testing programs. The effectiveness of these approaches have already been well-established in HIV self-  
60 testing programs (16).

61 Early on in the COVID-19 pandemic, contact tracing was used to limit onward transmission and link at-  
62 risk individuals to testing and care (17). Since then, both observational and modelling studies have  
63 shown that contact tracing is associated with better control of COVID-19 and is growing increasingly  
64 important for today's surveillance strategies to guide outbreak response. The impact of contract tracing  
65 is mediated by a number of factors, including the time it takes to identify and notify contacts and the  
66 number of positive cases that participate in contact tracing (18). During periods of peak transmission,  
67 contact tracing efforts may be slowed, stymied, or abandoned all together when the number of cases  
68 exceeds the public health system's capacity to identify and follow-up with exposed cases, as  
69 experienced during the omicron wave (19,20). In these cases, a self-testing regimen for exposed  
70 individuals may help interrupt transmission and control the outbreak.

71 In the context of contact tracing, self-testing facilitates even further decentralization of testing and  
72 allows for faster identification of infectious contacts, reaching at-risk populations, and generally  
73 mitigating unequal access to testing (15,21). However, to ensure equitable access to self-testing, the use  
74 of these steps must be integrated into public health system programs and strategies rather than simply  
75 making them available as a consumer product. This is particularly true in places where self-tests are  
76 difficult to obtain, either logistically or financially. Serial self-testing may also be advantageous to

77 contact-tracing efforts, as it allows exposed individuals to monitor themselves over time and does not  
78 rely on a single time point to determine infection status, particularly when individuals may not seek care  
79 during the recommended post-exposure period and the recommended on-label testing algorithm for  
80 many self-tests calls for testing twice in the event of a negative test. Serial self-testing as a part of a  
81 public health system contact tracing strategy may be a viable option to avoid multiple follow-up visits  
82 and allow both patients and healthcare providers to benefit from the decentralized and flexible nature  
83 of self-testing.

#### 84 Objectives and Hypothesis

85 The primary aim of this study is to evaluate the effectiveness of contact tracing supported by serial self-  
86 testing (testing daily for up to 10 days) among exposed individuals compared to routine contact tracing  
87 at one time point. This study also aims to evaluate the operational feasibility of self-testing for contact  
88 tracing within the Brazilian public health system, explore the barriers and facilitators at the provider and  
89 patient levels that mediate use of COVID-19 self-tests, and assess adherence to quarantine, isolation,  
90 and treatment guidelines. This study hypothesizes that serial self-testing of primary close contacts will  
91 identify more positive cases than routine contact tracing at a single timepoint post-exposure in a facility-  
92 based health care setting.

#### 93 Materials and Methods

##### 94 Design and Setting

95 This is a mixed-methods, two-arm randomized pragmatic trial within the public health system of two  
96 municipalities in Brazil. The study will be conducted at the Centro de Pesquisa em Medicina Tropical de  
97 Rondônia (CEPEM) in Porto Velho, Rondônia and several health units in Curitiba, Paraná. The health  
98 system within each municipality is structured through localized health units that are responsible for

99 providing care to a specific catchment area. Health units are generally staffed with nurses, technicians,  
100 community health workers, doctors, and pharmacists. Professional antigen testing for COVID-19 is  
101 widespread within the public health system and pharmacies, though RT-PCR testing remains the  
102 laboratory test of choice for patients in the acute phase with moderate to severe symptoms (22).  
103 Patients with no or mild symptoms may not receive a confirmatory PCR test and are typically advised to  
104 isolate (23). Contact tracing practices conducted by the public health system have varied between study  
105 sites based on health system capacity, COVID epidemiology, and caseload, though individuals have  
106 generally been instructed to notify their close contacts.

#### 107 Population

108 Patients aged 7 or older testing positive for COVID-19 at any participating health unit are eligible to be  
109 enrolled into the study as index cases. Approximately 604 close contacts of 150 index cases testing  
110 positive for COVID-19 will be enrolled. All index cases will complete a contact elicitation interview to  
111 identify close contacts who have been exposed to SARS-CoV-2. Close contacts will be invited to  
112 participate in the study following exposure notification. Close contacts of the index case will be eligible  
113 for enrollment as primary close contacts if they are 7 years of age or older and have been exposed to an  
114 enrolled index case within 2 days of index case symptom onset or within 7 days of index case positive  
115 test result. For the purposes of this study, “exposure” is defined as being within 1 meter of the index  
116 case for more than 15 minutes or having physical contact without appropriate personal protective  
117 equipment.

#### 118 Intervention

119 Primary close contacts will be randomized to either control or intervention. Randomization will be  
120 performed 1:1 at the index case level such that all primary close contacts of an index case are  
121 randomized to the same arm. This is the most practical way to randomize, as at least some primary close

122 contacts are expected to share a household with the index case and this approach will minimize  
123 contamination between the arms. The data manager will create the allocation sequence through  
124 computer-generated random numbers and will store this information in a locked Excel file. Only the data  
125 manager will have access to the full sequence. Study staff will reveal participant assignment upon  
126 enrollment by accessing a limited version of the file.

127 Primary close contacts randomized to the intervention arm will complete an enrollment visit either at  
128 the health unit or at home. Following consent, participants will complete a baseline questionnaire, a  
129 supervised ST and a health worker will independently perform a rapid test. The order in which these  
130 tests are conducted will be determined based on study ID and balanced within the arm to avoid test  
131 result bias related to sample depletion. Participants will then be provided with 10 STs to perform daily  
132 over the subsequent 10 days and will be contacted daily to complete a brief questionnaire.

133 The study will also provide additional tests to household members of primary close contacts randomized  
134 to the intervention arm and invite them to submit anonymous data around their use of the tests. These  
135 household members will not be consented or enrolled into the study and will receive no follow-up from  
136 the study team.

137 Primary close contacts randomized to the control arm will complete an enrollment visit either at the  
138 health unit or at home. Following consent, participants will complete a baseline questionnaire and a  
139 health worker will perform a rapid test. Participants will be contacted daily over the following 10 days to  
140 complete a brief study questionnaire. Figure 1 details the schedule of enrollment for each participant  
141 group and Figure 2 illustrates the overall study design.

142 *Fig 1. Schedule of Enrollment, Interventions, and Assessments.*

143 *Fig 2. Study Design.*

## 144 Outcomes

145 The primary outcome will be the proportion of primary exposure close contacts who test positive for  
146 COVID-19 per index case in the intervention arm compared to the control arm. This will be captured  
147 through the participant follow-up surveys. Subjects with missing outcome data will be excluded from  
148 analysis. For the purposes of analysis, participants in the intervention arm will be considered to have  
149 complete primary endpoint data if at least three test results are submitted over the 10-day follow-up  
150 period. For participants in the control arm, a professional Ag-RDT test result available at the enrollment  
151 visit will be considered complete.

152 Additional endpoints captured in the follow-up survey include proportion of close contacts testing  
153 positive who report adhering to recommended isolation guidelines and proportion of exposed contacts  
154 who report test results per local guidelines (intervention arm only). During the enrollment visit for  
155 participants randomized to the intervention, study staff will document whether the participant correctly  
156 performs the self-test (per the manufacturer's instructions for use) and the result of both self-test and  
157 professional rapid test to assess concordance between the two.

158 Acceptability, preferences, and user perspectives on self-testing will be assessed across stakeholders  
159 through focus group discussions; insights into user needs for instructions and training will be captured  
160 through user workshops.

## 161 Statistical Considerations

### 162 Sample Size

163 This study is powered to detect a 7.5% difference in positive cases identified between the intervention  
164 and control arm. This threshold was chosen through discussions with stakeholders to balance detection  
165 of a clinically meaningful outcome with an understanding of the likely rates of infection in a highly  
166 vaccinated population. Prior work at this site with COVID-19 testing of close contacts yielded a 30% PCR



167 positivity rate among close contacts during a period of low to moderate transmission. To account for  
168 increases in vaccination coverage, high rates of prior infection, and the likelihood of low transmission  
169 following the most recent wave, this population is estimated to have a 20% test positivity rate. Based on  
170 the established performance characteristics of Ag-RDTs, serial self-testing is estimated to identify up to  
171 75% of those cases. Using Equation 1, where  $z_{\alpha/2} = 1.96$  and  $z_{\beta} = 0.842$ , a total of 550 participants are  
172 needed (275 per Arm). To account for attrition in longitudinal data and exclusion of unevaluable cases,  
173 we will increase the sample size estimate by 10% to enroll a total of 604 close contacts (302 per Arm).  
174 To achieve this, approximately 150 index cases are needed, with each index case leading to an estimated  
175 average of 4 close contacts (75 per Arm). These estimations are based on prior work at the study  
176 site.(24)

177 *Equation 1: Sample Size Calculation for a Difference in Proportions*

$$178 \quad N = \frac{2 \left( \frac{z_{\alpha}}{2} + z_{\beta} \right)^2 * (p_0(1 - p_0) + (p_1(1 - p_1)))}{\Delta^2}$$

179 Sample size for the usability workshop will be 6-10 participants and sample size for focus groups will be  
180 up to 15 participants.(25)

181 Data Collection and Management

182 All data will be entered by study staff and participants or their caregivers directly into a secure,  
183 electronic database (REDCap) managed by the University of Washington Institute of Translational Health  
184 Sciences (25). Participants may opt to complete the follow-up survey by phone with study staff or by  
185 WhatsApp message link. For participants opting to receive the daily WhatsApp message, a message  
186 containing the survey link will be automatically sent each morning. If they do not complete the survey by  
187 the evening, they will be sent an automated reminder message. An automated script will alert the study  
188 team of any data anomalies (e.g., duplicate responses) and participant needs for follow-up (e.g.,

189 participant requested follow-up or participant has missed two or more consecutive surveys). Structuring  
190 the follow-up data collection in this way minimizes staff burden and may provide insights into how a  
191 similar system could be set up to have the greatest likelihood of influencing health behavior and  
192 ensuring test results are appropriately reported.

193 Secondary exposures will have the option to submit anonymous data by scanning a QR code to complete  
194 the survey, which may provide additional insight into alternative result reporting modalities. Usability  
195 workshops and focus group discussions will be recorded to ensure all detailed information can be  
196 captured appropriately.

#### 197 Safety Considerations

198 This study poses minimal risk to participant safety, as it does not involve any medical intervention and  
199 biological sampling is within acceptable ranges. Only research staff who have been trained in best  
200 practices for specimen collection and infection prevention will be involved in specimen collection. All  
201 records will be kept confidential at each site and the sponsor will not have access to any records that  
202 directly identify the research participants.

#### 203 Ethical Considerations

##### 204 Risks

205 Study procedures do not represent significant risks to the participants beyond those associated with a  
206 nasal swab, such as pain, discomfort, and nosebleed, which will be mitigated through user training on  
207 proper sample collection. All participants will be made aware that taking part in any study activity is  
208 voluntary. All study team members will adhere to institutional procedures for infection control and will  
209 have adequate personal protective equipment to minimize risks related to COVID-19 transmission.

210 All decisions regarding clinical care will be made through referral to the local public health system. The  
211 study team will review data in real-time to ensure that any information provided on clinical symptoms is  
212 referred appropriately per local public health guidelines.

213 Benefits

214 Participants in this study will have convenient access to COVID-19 testing following an exposure.  
215 Household contacts of these participants will also have access to free COVID-19 STs should they wish to  
216 use them. There is no direct benefit to the community, however there may be indirect benefits by  
217 identifying more positive cases, which could reduce the spread of COVID-19 in the community.

218 Special Considerations for Enrolling Minors

219 The consent/assent process for this study is tailored to three different age groups that may be enrolled,  
220 per Brazilian regulations. For the youngest age group assenting (7-11 years of age), the caregiver  
221 (parent/legal guardian giving consent) will perform the self-test on the child. The other two age groups  
222 (12-14 and 15-17 years of age) will perform the self-test on themselves, though they may receive help  
223 from their caregiver as needed. This determination is consistent with what would reasonably be  
224 expected of these age groups and Brazilian research ethics regulations. Additionally, the self-tests being  
225 used in this study are indicated for children 2 years and older with adult supervision, so all use during  
226 this study will be on-label.

227 Enrolling children does not sufficiently alter the risk-benefit ratio to warrant excluding children from this  
228 study. The only additional risk this study poses to children is that they may be more likely to use the test  
229 incorrectly, which will be mitigated by conducting the test with caregiver supervision. Children may also  
230 benefit from the findings of this research given their participation in school and social group activities  
231 and they have been disproportionately affected by the pandemic due to school closures. This study will  
232 show how serial self-testing can be used in families and whether it can be operationalized to be

233 effective. Therefore, it would be unethical to exclude children from this study given their potential to  
234 benefit from the findings and minimal additional risk posed to them.

## 235 Study Timeline

236 This study has been approved by The National Commission for Research Ethics (CONEP, Brazil's national  
237 Institutional Review Board [IRB], approval number 59179922.9.1001.0011), the local IRBs in Porto Velho  
238 and Curitiba, and the WHO Ethics Review Committee. The study began recruitment December 5, 2022,  
239 and will run for approximately six months.

## 240 Study Registration

241 This study is registered at ISCTRN (ISRCTN91602092).

## 242 Discussion

### 243 Impact

244 This novel approach to contact tracing attempts to increase equitable access to essential diagnostics in  
245 the face of the worst pandemic in recent history. This study will generate data around the operational  
246 feasibility and effectiveness of a serial self-testing strategy in the context of the Brazilian public health  
247 system. While providing patients with 10 self-tests to perform daily is likely impractical, we are hoping  
248 further sensitivity analyses may reveal more optimal testing strategies to inform appropriate resource  
249 allocation. The study ultimately aims to generate evidence to support health policy makers in Brazil to  
250 understand whether this is a feasible tool to incorporate into the unified health system to support public  
251 health contact tracing/outbreak response efforts, which would reduce barriers to ST access and  
252 promote use of STs. Finally, this study will join a growing body of evidence being generated to find  
253 optimal self-testing algorithms as part of non-pharmaceutical interventions to mitigate onward  
254 community transmission of COVID-19 (10,11). Evidence from these studies will be critical to inform

255 policy and public health practice around the use and merits of self-testing through an epidemiological  
256 lens (2).

257 Limitations

258 Study activities will be impacted by changing public health policies and guidelines as well as the evolving  
259 epidemiology of COVID-19. Where possible, these will be monitored throughout the study and tracked  
260 both administratively and through participant surveys. The methods outlined in this protocol are  
261 designed to be flexible enough to adapt to the local COVID-19 situation as needed while maintaining  
262 sufficient scientific rigor to fulfill study objectives. Additionally, follow-up data may be biased due to  
263 both the nature of being self-reported as well as observed. Data from secondary exposures may also be  
264 influenced by the fact their household member is participating in a research study. Finally, performing  
265 daily self-tests for 10 days is not a cost-effective method of contact tracing. This strategy was selected in  
266 the interest of generating a robust data set with the potential to conduct additional analyses regarding  
267 cost effective testing strategies. Commodity costs will also be tracked to support these ancillary  
268 analyses.

269 Dissemination, stakeholder, and participant engagement

270 Stakeholders from the local municipalities and the Ministry of Health have been engaged throughout  
271 protocol development to better understand the local health system perspective when building the  
272 study's objectives and methodology. These channels of communication will remain open throughout the  
273 conduct of the study to ensure continued engagement, and results will be shared back with these  
274 stakeholders. Research results will be shared locally, at the participating facilities and health units  
275 through debrief meetings and short reports. In addition to local results sharing, study findings will be  
276 disseminated through a variety of channels, including engagement with the World Health Organization,  
277 donors, and peer-reviewed publications. At the close of their participation, participants will also be sent

278 information about where they can find final study results and be notified of dissemination outputs and  
279 events.

## 280 Acknowledgements

281 The authors would like to acknowledge the Coordination of Respiratory Diseases from the Ministry of  
282 Health of Brazil and the Health Secretariats from Porto Velho and Curitiba Municipalities for their  
283 valuable contributions throughout the protocol development process. The authors also acknowledge  
284 Stephanie Zobrist and Gonzalo Domingo for their technical guidance in the development of this protocol  
285 and Krista Granger for her project coordination support.

## 286 References

- 287 1. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues  
288 and Challenges. *J Clin Microbiol.* 2020 May 26;58(6):e00512-20.
- 289 2. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for  
290 Containment. *N Engl J Med.* 2020 Nov 26;383(22):e120.
- 291 3. Peeling RW, Olliaro P. Rolling out COVID-19 antigen rapid diagnostic tests: the time is now. *Lancet*  
292 *Infect Dis.* 2021 Aug;21(8):1052–3.
- 293 4. Bekliz M, Perez-Rodriguez F, Puhach O, Adea K, Marques Melancia S, Baggio S, et al. Sensitivity of  
294 SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. *medRxiv.* 2022 Jan 17;
- 295 5. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. The Abbott PanBio WHO  
296 emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2-  
297 Evaluation of the accuracy and ease-of-use. *PLoS One.* 2021;16(5):e0247918.
- 298 6. Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, et al. Accuracy of  
299 novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. *PLOS*  
300 *Medicine.* 2021 Aug 12;18(8):e1003735.
- 301 7. Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-Testing as an Invaluable  
302 Tool in Fighting the COVID-19 Pandemic. *J Prim Care Community Health.* 2021  
303 Dec;12:21501327211047784.
- 304 8. Wanat M, Logan M, Hirst JA, Vicary C, Lee JJ, Perera R, et al. Perceptions on undertaking regular  
305 asymptomatic self-testing for COVID-19 using lateral flow tests: a qualitative study of university  
306 students and staff. *BMJ Open.* 2021 Sep 2;11(9):e053850.

- 307 9. Shilton S, Ivanova Reipold E, Roca Álvarez A, Martínez-Pérez GZ. Assessing Values and Preferences  
308 Toward SARS-CoV-2 Self-testing Among the General Population and Their Representatives, Health  
309 Care Personnel, and Decision-Makers: Protocol for a Multicountry Mixed Methods Study. *JMIR Res*  
310 *Protoc.* 2021 Nov 26;10(11):e33088.
- 311 10. Ciccone EJ, Conserve DF, Dave G, Hornik CP, Kuhn ML, Herling JL, et al. At-home testing to mitigate  
312 community transmission of SARS-CoV-2: protocol for a public health intervention with a nested  
313 prospective cohort study. *BMC Public Health.* 2021 Dec 4;21(1):2209.
- 314 11. Gross R. Secondary Distribution of COVID-19 Self-tests vs. Referrals to Increase Test Uptake in  
315 Underserved Populations [Internet]. *clinicaltrials.gov*; 2022 May [cited 2022 Dec 19]. Report No.:  
316 NCT04797858. Available from: <https://clinicaltrials.gov/ct2/show/NCT04797858>
- 317 12. At-home COVID tests are a free, easy part of everyday life in the U.K., and the U.S. has taken note  
318 [Internet]. [cited 2022 Dec 20]. Available from: [https://www.cbsnews.com/news/at-home-covid-](https://www.cbsnews.com/news/at-home-covid-tests-are-a-free-easy-part-of-everyday-life-in-the-uk-and-the-us-has-taken-note/)  
319 [tests-are-a-free-easy-part-of-everyday-life-in-the-uk-and-the-us-has-taken-note/](https://www.cbsnews.com/news/at-home-covid-tests-are-a-free-easy-part-of-everyday-life-in-the-uk-and-the-us-has-taken-note/)
- 320 13. Sibanda E, Choko AT, Watadzaushe C, Mukoka M, Kumwenda M, Abok F, et al. Use of SARS-CoV-2  
321 antigen-detection rapid diagnostic tests for COVID-19 self-testing: interim guidance, 9 March 2022:  
322 web annex B: COVID-19 self-testing using antigen rapid diagnostic tests: feasibility evaluation  
323 among health-care workers and general population in Malawi and Zimbabwe. 2022 [cited 2022 Jul  
324 20]; Available from: [https://policycommons.net/artifacts/2270225/use-of-sars-cov-2-antigen-](https://policycommons.net/artifacts/2270225/use-of-sars-cov-2-antigen-detection-rapid-diagnostic-tests-for-covid-19-self-testing/3030039/)  
325 [detection-rapid-diagnostic-tests-for-covid-19-self-testing/3030039/](https://policycommons.net/artifacts/2270225/use-of-sars-cov-2-antigen-detection-rapid-diagnostic-tests-for-covid-19-self-testing/3030039/)
- 326 14. WHO issues its first emergency use listing for a SARS-CoV-2 self-test [Internet]. WHO -  
327 Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector  
328 Control). 2022 [cited 2022 Jul 20]. Available from: [https://extranet.who.int/pqwweb/news/who-](https://extranet.who.int/pqwweb/news/who-issues-its-first-emergency-use-listing-sars-cov-2-self-test)  
329 [issues-its-first-emergency-use-listing-sars-cov-2-self-test](https://extranet.who.int/pqwweb/news/who-issues-its-first-emergency-use-listing-sars-cov-2-self-test)
- 330 15. Pray IW, Ford L, Cole D, Lee C, Bigouette JP, Abedi GR, et al. Performance of an Antigen-Based Test  
331 for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin,  
332 September-October 2020. *MMWR Morb Mortal Wkly Rep.* 2021 Jan 1;69(5152):1642–7.
- 333 16. World Health Organization. Consolidated guidelines on HIV testing services [Internet]. [cited 2023  
334 Feb 2]. Available from: <https://www.who.int/publications-detail-redirect/978-92-4-155058-1>
- 335 17. Juneau CE, Pueyo T, Bell M, Gee G, Collazzo P, Potvin L. Evidence-Based, Cost-Effective  
336 Interventions To Suppress The COVID-19 Pandemic: A Systematic Review. 2020.
- 337 18. Juneau C, Briand A, Pueyo T, Collazzo P, Potvin L. Effective Contact Tracing for COVID-19: A  
338 Systematic Review. *medRxiv.* 2020;
- 339 19. World Health Organization. Contact tracing and quarantine in the context of the Omicron SARS-  
340 CoV-2 variant: interim guidance, 17 February 2022 [Internet]. World Health Organization; 2022  
341 [cited 2022 Dec 9]. Report No.: WHO/2019-  
342 nCoV/Contact\_tracing\_and\_quarantine/Omicron\_variant/2022.1. Available from:  
343 <https://apps.who.int/iris/handle/10665/351949>

- 344 20. Olivo A. Amid omicron surge, contact tracing is more complicated, officials say. Washington Post  
345 [Internet]. 2022 Jan 7 [cited 2022 Dec 9]; Available from: [https://www.washingtonpost.com/dc-  
md-va/2022/01/07/omicron-contact-tracing-covid-surge/](https://www.washingtonpost.com/dc-<br/>346 md-va/2022/01/07/omicron-contact-tracing-covid-surge/)
- 347 21. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment of COVID-  
348 19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After  
349 Symptom Onset. JAMA Internal Medicine. 2020 Sep 1;180(9):1156–63.
- 350 22. Brazilian Ministry of Health. Epidemiological Surveillance Guide. 2022.
- 351 23. Recommendations for Isolation of COVID-19 Cases. 2022 Jan 10.
- 352 24. Zobrist S, Oliveira-Silva M, Vieira AM, Bansil P, Gerth-Guyette E, Leader BT, et al. Screening for  
353 SARS-CoV-2 in close contacts of individuals with confirmed infection: performance and operational  
354 considerations [Internet]. medRxiv; 2022 [cited 2022 Mar 25]. p. 2022.01.27.22269904. Available  
355 from: <https://www.medrxiv.org/content/10.1101/2022.01.27.22269904v1>
- 356 25. Virzi RA. Refining the Test Phase of Usability Evaluation: How Many Subjects Is Enough? Hum  
357 Factors. 1992 Aug 1;34(4):457–68.
- 358
- 359 **S1 Protocol.** Approved study protocol.
- 360 **S2 Consent.** Example consent form used in study.
- 361 **S3 SPIRIT Checklist.**



Group	Activity	D0	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	Off-Study
<b>Index Case</b>	Eligibility Screen	X											
	Informed Consent	X											
	Contact Elicitation	X											
	Questionnaire	X											
	Randomization (of close contacts)	X											
	Follow-Up Survey		X	X	X	X	X	X	X	X	X	X	
	GPS Screening & Enrollment												X
<b>Close Contact</b>	Eligibility Screen	X											
	Informed Consent	X											
	Questionnaire	X											
	GPS Screening & Enrollment												X
<i>Arm 1: Control</i>	Professional Ag-RDT	X											
	Follow-Up Survey		X	X	X	X	X	X	X	X	X	X	
<i>Arm 2: Intervention</i>	Professional Ag-RDT	X											
	Supervised Self-Test	X											
	Provision of Self-Tests for Follow-Up Period and 2° Exposures	X											
	Follow-Up Survey		X	X	X	X	X	X	X	X	X	X	
<b>Secondary Exposures</b>	Voluntary completion of QR-code based survey	<i>May occur at any timepoint they use a test</i>											

Figure 1




Figure 2